Enochian BioSciences, Inc. announced on Monday that the Food and Drug Administration accepted a pre-investigational new drug request for a potential treatment for HIV.Pre-investigational new drug requests are very early stage communications between the Office of Infectious Diseases and creators of new treatments.
The company expects comments from the administration sometime this fall.Enochian Biosciences specializes in gene-modified cellular and immune therapies in infectious diseases and cancers.Dr.
Serhat Gumrukçu, co-founder of the company, submitted the request based on the findings of a 54-year-old man with HIV who achieved viral control for 255 days due to treatment with Natural Killer and Gamma Delta T-cells, according to a company.